Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated May 05, 2026, titled "PRESS RELEASE REGARDING COMPANY S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., SUCCESSFULLY COMPLETED AN UNANNOUNCED GOOD MANUFACTURING PRACTICE (GMP) INSPECTION BY CHINA S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) FOR ITS SHANGHAI SITE, CHINA".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dishman Carbogen Amcis Limited's wholly-owned subsidiary CARBOGEN AMCIS (Shanghai) has successfully completed an unannounced GMP inspection by China's National Medical Products Administration (NMPA) on April 14, 2026. The inspection covered API manufacturing operations and the site's Quality System including facilities, quality control laboratories, documentation practices, and quality management systems. The inspection concluded with zero observations and no issues requiring formal explanation. The Shanghai facility plays a key role in CARBOGEN AMCIS' global network, supporting API manufacturing and process development activities. Management called this a significant achievement that validates their global quality culture.
This clean GMP inspection outcome strengthens customer confidence in the Shanghai facility as a reliable partner for global pharmaceutical companies and supports the company's continued growth in China and international markets. It also validates the site's operational consistency and regulatory readiness.